HUTCHMED (China) Limited (GB:HCM) has released an update.
HUTCHMED (China) Limited has announced significant board changes with the retirement of long-serving Chairman Mr. Simon To and the appointment of Dr. Dan Eldar as his successor. Dr. Eldar brings over 30 years of experience in various sectors, including biotechnology and healthcare, to his new role as Chairman. The company expressed its gratitude to Mr. To for his contributions and looks forward to Dr. Eldar’s leadership in advancing HUTCHMED’s mission in the biopharmaceutical industry.
For further insights into GB:HCM stock, check out TipRanks’ Stock Analysis page.
